Anika Therapeutics Inc.

Historical 13F Holders

Symbol
ANIK
CUSIP
035255108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 035255108 since 12/18/2024, newest first.

Filer % of Class Filed
Vanguard Capital Management LLC 13G/A Amendment 1 4.95% 7/31/2026
Event 6/30/2026
BlackRock Portfolio Management LLC 13G/A Amendment 1 4.1% 7/17/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.2% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 8 0% 3/26/2026
Event 3/13/2026
Caligan Partners LP 13D/A Amendment 5
10.0% 1/27/2026
Event 1/23/2026
Trigran Investments, Inc. 13G/A Amendment 4
1.2% 1/8/2026
Event 12/31/2025
Caligan Partners LP 13D/A Amendment 4
10.0% 11/21/2025
Event 11/19/2025
Trigran Investments, Inc. 13G/A Amendment 3
11.2% 11/7/2025
Event 9/30/2025
BlackRock Portfolio Management LLC 13G 5.5% 10/17/2025
Event 9/30/2025
BlackRock, Inc. 13G/A Amendment 7 6.8% 4/17/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 6 10.6% 2/5/2025
Event 12/31/2024
Dimensional Fund Advisors LP 13G/A Amendment 12 4.5% 1/23/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 4 4.20 k $82.5 k
2026 Q2 135 12.3 M $180 M
2026 Q1 131 12.4 M $179 M
2025 Q4 128 12.3 M $118 M
2025 Q3 118 12.3 M $115 M
2025 Q2 106 12.8 M $136 M
2025 Q1 111 12.7 M $191 M
2024 Q4 114 12.6 M $207 M
2024 Q3 126 13.1 M $324 M
2024 Q2 121 13.8 M $349 M
2024 Q1 129 14.8 M $377 M
2023 Q4 124 13.8 M $314 M
2023 Q3 120 13.0 M $242 M
2023 Q2 121 13.1 M $340 M
2023 Q1 128 13.1 M $377 M
2022 Q4 131 14.0 M $415 M
2022 Q3 128 14.1 M $335 M
2022 Q2 129 13.5 M $302 M
2022 Q1 122 13.6 M $342 M
2021 Q4 130 13.5 M $485 M
2021 Q3 136 13.2 M $560 M
2021 Q2 141 13.1 M $569 M
2021 Q1 156 13.3 M $543 M
2020 Q4 177 14.4 M $654 M
2020 Q3 167 13.6 M $482 M
2020 Q2 171 13.9 M $525 M
2020 Q1 176 13.2 M $381 M
2019 Q4 206 13.9 M $720 M
2019 Q3 208 13.9 M $761 M
2019 Q2 183 14.2 M $575 M
2019 Q1 170 13.4 M $405 M
2018 Q4 168 12.9 M $435 M
2018 Q3 173 13.4 M $566 M
2018 Q2 180 14.2 M $455 M
2018 Q1 175 12.5 M $623 M
2017 Q4 176 12.4 M $670 M
2017 Q3 172 12.4 M $726 M
2017 Q2 165 12.4 M $613 M
2017 Q1 163 11.9 M $519 M
2016 Q4 167 11.5 M $562 M
2016 Q3 168 11.1 M $530 M
2016 Q2 166 11.5 M $619 M
2016 Q1 168 12.9 M $576 M
2015 Q4 159 13.2 M $475 M
2015 Q3 141 12.5 M $402 M
2015 Q2 140 12.1 M $401 M
2015 Q1 164 12.3 M $505 M
2014 Q4 164 11.9 M $483 M
2014 Q3 158 11.2 M $409 M
2014 Q2 168 10.2 M $473 M
2014 Q1 159 10.2 M $417 M